We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
NewAmsterdam Pharma Company N.V. (NAMS - Free Report) shares ended the last trading session 5.9% higher at $32.48. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.6% gain over the past four weeks.
The sudden rise in the stock price can be attributed to growing investor optimism regarding the potential of NewAmsterdam Pharma Company’s only investigational candidate, obicetrapib. The candidate is currently being studied as a potential treatment to lower LDL-C as an adjunct to maximally tolerated lipid-lowering therapies in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia across three pivotal late-stage studies.
This company is expected to post quarterly loss of $0.41 per share in its upcoming report, which represents a year-over-year change of -127.8%. Revenues are expected to be $2.35 million, down 91.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For NewAmsterdam Pharma Company N.V., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NAMS going forward to see if this recent jump can turn into more strength down the road.
NewAmsterdam Pharma Company N.V. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Stevanato Group (STVN - Free Report) , closed the last trading session 5.6% lower at $24.53. Over the past month, STVN has returned 7.6%.
Stevanato's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.15. Compared to the company's year-ago EPS, this represents a change of +15.4%. Stevanato currently boasts a Zacks Rank of #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock?
NewAmsterdam Pharma Company N.V. (NAMS - Free Report) shares ended the last trading session 5.9% higher at $32.48. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.6% gain over the past four weeks.
The sudden rise in the stock price can be attributed to growing investor optimism regarding the potential of NewAmsterdam Pharma Company’s only investigational candidate, obicetrapib. The candidate is currently being studied as a potential treatment to lower LDL-C as an adjunct to maximally tolerated lipid-lowering therapies in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia across three pivotal late-stage studies.
This company is expected to post quarterly loss of $0.41 per share in its upcoming report, which represents a year-over-year change of -127.8%. Revenues are expected to be $2.35 million, down 91.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For NewAmsterdam Pharma Company N.V., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NAMS going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
NewAmsterdam Pharma Company N.V. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Stevanato Group (STVN - Free Report) , closed the last trading session 5.6% lower at $24.53. Over the past month, STVN has returned 7.6%.
Stevanato's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.15. Compared to the company's year-ago EPS, this represents a change of +15.4%. Stevanato currently boasts a Zacks Rank of #2 (Buy).